论文部分内容阅读
目的评价分析他汀类药物对不同体质量指数及转氨酶轻中度升高的高脂血症患者肝脏安全性有无影响。方法入选于河南省人民医院首次诊断的高脂血症患者130人,根据体质量指数分为三组,即正常组、超重组、肥胖组,分别检测治疗前、治疗8周、24周时的血脂及肝脏转氨酶水平,比较不同体质量指数的高脂血症患者在他汀治疗时肝脏安全性,并观察他汀类药物对基线转氨酶轻中度升高者有无影响。结果治疗前超重患者转氨酶轻中度升高发生率高于较正常体质量指数患者(4.6%vs1.5%),不同体质量指数组间转氨酶升高比较差异无统计学意义(P>0.05),6个治疗前转氨酶轻度升高患者在治疗24周后恢复正常水平,另外有6个治疗前转氨酶正常患者在治疗24周后出现轻中度升高。结论临床常用剂量他汀类药物降脂治疗对肥胖及转氨酶轻中度升高的高脂血症患者肝脏功能无影响。
Objective To evaluate whether statins have any effect on hepatic safety in patients with hyperlipidemia who have different body mass index and mildly elevated transaminases. Methods One hundred and thirteen patients with hyperlipidemia who were diagnosed for the first time in Henan Provincial People’s Hospital were divided into three groups according to body mass index (normal group, overweight group and obesity group) Blood lipids and liver aminotransferase levels in patients with hyperlipidemia compared with different body mass index during the statin treatment of liver safety and to observe the statins on the baseline aminotransferase mildly elevated have no effect. Results The incidence of mild to moderate transaminase in overweight patients before treatment was higher than that in patients with normal body mass index (4.6% vs 1.5%). There was no significant difference in ALT between different body mass index groups (P> 0.05) , Six patients with mildly elevated aminotransferases before treatment returned to normal after 24 weeks of treatment, and six patients with normal aminotransferases had mild to moderate increases after 24 weeks of treatment. Conclusion The common clinical dose of statins lipid-lowering therapy has no effect on the liver function in patients with obesity and mild to moderate hyperlipidemia.